Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up ...

BV500 reaches second milestone, with the advancement of multiple broadly profiled and highly potent oral Lead candidates with demonstrated broad-spectrum in vitro and in vivo efficacy against ...

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

The AI model works by examining each video frame to find important features of the lungs and assesses the order of the video ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

Boehringer Ingelheim said its experimental treatment for a chronic lung disease succeeded in a pivotal study, and it's taking ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Pliant (PLRX) stock plunged 61% on news it has paused enrollment in a Phase 2b study of its drug bexotegrast in patients with ...

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...